Get started

Johnson_and_johnson

Johnson & Johnson (JNJ) - Approaching the Reversal ZoneIn April, we anticipated a pullback for JNJ, and since then, the stock has dropped approximately 7%, aligning with our expectations. The current trend suggests further downward movement, reinforcing our previous analysis. We are focusing on the support zone ranging from $134 to $116, with a potential lower bound at $109, the Corona-Low. The ongoing pullback could represent the completion of Wave (4) within this target zone, aligning with multiple levels. We are going to be monitoring this for signs of a reversal within this zone. This zone will be crucial to confirm the next possible upward movement.
NYSE:JNJLong
by freeguy_by_wmc
1
Johnson & Johnson's Q1 Triumph: Surpassing ExpectationsJohnson & Johnson (NYSE: NYSE:JNJ ) has kicked off 2024 with a resounding victory, showcasing robust first-quarter earnings that outpaced Wall Street estimates and signaling a promising trajectory for the rest of the year. The pharmaceutical giant reported an impressive adjusted EPS of $2.71, marking a remarkable 12.4% surge compared to the previous year. This stellar performance surpassed analysts' projections of $2.64, underscoring the company's resilience and strategic prowess. In terms of revenue, Johnson & Johnson ( NYSE:JNJ ) posted sales of $21.38 billion, reflecting a steady 2.3% increase year over year. While this figure nearly mirrored market expectations, the operational growth of 3.9% and adjusted operational growth of 4.0% underscored the company's underlying strength and adaptability in navigating market dynamics. One of the standout performers in Johnson & Johnson's portfolio was its Innovative Medicine segment, which witnessed robust operational sales growth of 8.3% to reach $13.6 billion. Notably, sales of key drugs such as Stelara and Darzalex demonstrated resilience, with the latter experiencing a notable 19% surge in revenue. Moreover, the company's medical devices business proved to be a significant driver of growth, generating sales of $7.82 billion during the quarter, marking a commendable 4.5% year-over-year increase. This uptick was fueled by strong performances in electrophysiology products and cardiovascular solutions, showcasing Johnson & Johnson's ( NYSE:JNJ ) diverse revenue streams and market leadership in healthcare innovation. In a move sure to delight investors, Johnson & Johnson ( NYSE:JNJ ) announced a 4.2% increase in its quarterly dividend, a testament to its commitment to delivering value to shareholders amidst a challenging economic landscape. Looking ahead, Johnson & Johnson ( NYSE:JNJ ) raised its fiscal year 2024 guidance, projecting operational sales in the range of $88.7 billion to $89.1 billion and adjusted EPS between $10.57 and $10.72. This optimistic outlook, coupled with the company's track record of delivering on its promises, instills confidence in its ability to navigate future opportunities and challenges. Despite a slight dip in premarket trading following the earnings release, Johnson & Johnson's ( NYSE:JNJ ) strong performance in Q1 sets a solid foundation for continued success, reaffirming its position as a leader in the healthcare industry and a reliable investment choice for shareholders worldwide.
NYSE:JNJ
by DEXWireNews
Rallybio's Breakthrough Collaboration Drives $RLYB Stock SurgeRallybio Corporation (Nasdaq: NASDAQ:RLYB ) is hitting the accelerator pedal after announcing a groundbreaking collaboration with Johnson & Johnson to combat fetal and neonatal alloimmune thrombocytopenia (FNAIT). In a strategic move aimed at advancing therapeutic solutions for pregnant individuals at risk of FNAIT, Rallybio revealed plans for RLYB212, a revolutionary human monoclonal antibody designed to prevent alloimmunization and eliminate the risk of FNAIT in fetuses and newborns. The partnership with Johnson & Johnson not only includes a significant equity investment but also underscores a joint commitment to tackle this severe and rare disease. Rallybio's CEO, Stephen Uden, expressed enthusiasm about the collaboration, emphasizing its potential to drive awareness, accelerate research, and ultimately, eradicate FNAIT. RLYB212 stands out as the only investigational therapy targeting pregnant individuals at risk of FNAIT who have not yet alloimmunized. This innovative approach complements Johnson & Johnson's ongoing Phase 3 study of nipocalimab, targeting FcRn, in pregnant individuals already alloimmunized. Rallybio's natural history study is a crucial step in gathering data to support future registration of RLYB212. The study's focus on a diverse population underscores the company's commitment to inclusivity and comprehensive research. The collaboration between Rallybio and Johnson & Johnson represents a significant leap forward in addressing FNAIT, offering hope to pregnant individuals and their newborns. As Rallybio continues to drive innovation in therapeutic solutions, investors are optimistic about the company's potential to transform the landscape of rare disease treatment.
NASDAQ:RLYBLong
by DEXWireNews
J&JOHNSON, Ascending-Triangle-Formation, Completion Incoming!Hello, Welcome to this analysis about the stock JOHNSON&JOHNSON, looking at the 4-hour timeframe perspectives. In my analysis recently I detected an interesting formational structure with J&J which has the ability to show up a determined breakout. As the corona pandemic moved on there emerged several pharmacy companies wanted to invent the covid-19 vaccines, one of them is J&J, now as these vaccines finally emerged there have been sharp rallies in the other companies already especially when the demand at the beginning of the vaccine launches has risen. Now as the demand keeps increasing and the companies distribute to new markets these demand-runs come in waves, as traders we can catch such opportunities in the market when the fundamental signs also give a positive indication for a rise or a fall in a stock like it is the case with these pharmacy companies in the last months. From the technical point of view, J&J is building this massive ascending-triangle-formation with the waves A to C already completed. Now J&J is about to form the wave D and this wave D so far has shown up with increased volatility to the upside which is a good sign. Furthermore, J&J managed to bounce in the 200-EMA and the next time we can expect the stock to rightly test the upper-boundary as it is marked in my chart from where the wave E will have its origins, when then the wave E manages to stay in the channel and possibly also bounce in the blue confirmational-bounce-cluster this can lead to the final breakout and completion of the ascending-triangle-formation. In this case it is highly necessary that there do not come any bad news for the vaccine distribution such as a break in the supply chain or something else that can lead to a decline in the stock, when this not happens the breakout is likely to show up after the wave-count completed. In this manner, thank you for watching my analysis about JOHNSON&JOHNSON with the current fundamental aspect as well as the major triangle-formation forming, will be great when you support it with a like and follow or comment, great contentment for everybody supporting, all the best! "There are many roads to prosperity, but one must be taken." Information provided is only educational and should not be used to take action in the markets.
NYSE:JNJ
by VincePrince
4
J&JOHNSON, Stronger Than The Rest Market, Possible Bull-Flag!Hello, Traders Investors And Community, welcome to this analysis about the recent events, the current price-structure and what we can expect the next hours and days within J&JOHNSON. As I already mentioned in previous analysis in the current corona-crisis there are gainers and losers who are profiting either out of the crisis or having deficiencies to catch up onto the level seen before the corona-fears hit the markets. Therefore we see a paradigm shift in the global economy similar to these ones we have seen in the past where there have been companies which gone bankrupt due to lack of resilience and others which survived the crisis and exist still today, this was a constant repetition in the financial-crashes we have seen in history and it is repeating itself right now as history does not change at all only marginally when the necessities desire different circumstances. Therefore we have stocks that perform better than the markets, which are the truffles within this situation where we should keep an eye on when considering something on the long side and there are others that cant catch up with the train and consolidating or downshift. Example Stock: Weaker Than Rest Market: BERKSHIRE (4-Hour Timeframe): When looking at my chart you can see that J&J is trading above the 800-EMA marked in black which firstly is a strong sign that the stock holds above the EMA, furthermore, we have the 100-EMA which you see marked in green within the structure of my chart which provided a failed bearish-cross, this is a bullish sign indicating that the bulls are stronger than the bears. It is also the major difference to BERKSHIRE where the 100-EMA crossed the 800-EMA to the downside and provided a bearish crossover signal since which the stock didn't take these EMAs out this gives adds a more bullish edge to J&J at the moment which is trading in a possible bull-flag right now which you can see marked in blue. The next time we can expect the stock to test the support it has remaining in the 138 level and the 800-EMA after forming the wave D of its overall wave count. When this test provides successful and solidity confirms at that level it is within the possible spectrum that J&J moves higher to confirm the huge possible bull-flag in which it is trading at the moment, this scenario will play out when the stock crosses with good volatility and sustainable above the higher boundary of the channel. When the stock provides such a breakout it will move onto its targets within the all-time-high range with a high possibility and even higher after that when there confirm good bullish volatility and no other meaningful bearish signs which alter the situation again. Taking all these factors into consideration we have a technical basis for J&J to succeed next times although because it is the pharmaceutical company with the biggest market and as I already pointed out in past analysis these are stocks which can provide gains also in the current corona-crisis and show a possible anticyclical movement compared to the average rest market. In comparison with the S&P 500 which is still below its all-time high, we have a stronger picture here at the moment. We will see how this will develop further the next time and if J&J provides to hold this strong environment. Although there can still show new volatility to the downside in the average market due to upcoming corona-restriction this can add to J&J but as it is a possible anticyclical market mover the volatility to the downside can proof not that devastatingly fatal. In this manner, thank you for watching, support for more market insight, good day, and all the best! “Learning is an ornament in prosperity, a refuge in adversity, and a provision in modern markets.” Information provided is only educational and should not be used to take action in the markets.
NYSE:JNJ
by VincePrince
17
KVUE Split-off: A Response to JNJ's Cancer-Related Products?It is plausible to consider that Johnson & Johnson's decision to spin off Kenvue might be linked to an effort to mitigate potential legal liabilities stemming from its talc-based products, which have been implicated in cases of cancer in the US and Canada. This strategic maneuver could potentially offer a layer of legal protection. Shareholders are expected to transition from holding Johnson & Johnson shares to Kenvue shares in the upcoming week. A similar approach was attempted by MMM, although it did not yield successful results, causing a downward trajectory in its stock performance over the past two years. From my perspective, the true rationale behind the division appears to be related to the numerous instances of individuals developing cancer due to Johnson & Johnson's talc-based products. A recent legal ruling mandated Johnson & Johnson to pay $18.8 million to a California resident who claimed to have contracted cancer from using its baby powder. This decision represents a setback for the company as it seeks resolution for thousands of comparable cases related to its talc-based products within a US bankruptcy court. Johnson & Johnson recently disclosed detailed information regarding the much-anticipated division of its consumer healthcare venture, Kenvue. This move involves a separation of at least 80.1% of Kenvue shares, facilitated through an exchange offer presented to investors. Within this arrangement, shareholders have the flexibility to trade all, a portion, or none of their Johnson & Johnson shares for Kenvue stock. The company is extending the choice to its investors, allowing them to opt for an exchange of shares for Kenvue stock. To incentivize this exchange, a 7% discount is being offered on the shares. However, there is an upper threshold of 8.0549 Kenvue shares for each Johnson & Johnson share. If this ceiling is not applicable, shareholders will receive approximately $107.53 worth of Kenvue shares for every $100 worth of Johnson & Johnson stock they intend to exchange. The execution of this exchange offer is anticipated to conclude by mid-August. Notably, this exchange program is voluntary and carries tax-free advantages. Kenvue has outlined plans to distribute a portion of its available funds to shareholders through dividend payments. The company has recently initiated a quarterly dividend of $0.20 per share (equivalent to $0.80 annually), with the first payout scheduled for early September. This dividend framework translates to a dividend yield of 3.3% based on the prevailing stock price of approximately $24 per share. This yield marginally exceeds Johnson & Johnson's existing dividend yield of 2.8%. It is likely that a significant portion of individuals holding Johnson & Johnson stock will opt to exchange their shares for Kenvue. Based on this assessment, I anticipate that Kenvue's stock could potentially reach $30 in the near future. Looking forward to read your opinion about it!
NYSE:KVUELong
by TopgOptions
JNJ | I Love It Here | LONGJohnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
NYSE:JNJLong
by DivergenceSeeker
2
Johnson & Johnson (JNJ) | Inside an Optimal Buying Zone!Hi, The market has made some pretty good moves up and the current slight correction is bringing prices back to technically good levels and Johnson & Johnson is one of them. Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer goods. Technically, it has been quite difficult to get it (when there has been such a clear and strong trend, you don't have to be smart to understand that the fundamentals are fine with JNJ), because there have not been such sharp reversals, from which to find a support level and etc, but as you can see from the picture, it has not been impossible. Namely, the price of JNJ has respected a trendline for almost 10 years. The trend line is drawn from the closing prices (you can do it easily on the line chart) to eliminate the noise and the wicks that the various waves of panic have brought. JNJ has always been bought up very quickly and the growth has been steady. Also, the price has respected the 50-month moving average (50EMA) almost flawlessly, and at the moment the trend line and the EMA50 form a single punch and are together in one price zone. Technical criteria for a significant level of support: 1. Trendline, clearly proven in the long term. 2. The Monthly EMA50 has held nicely. 3. The resistance level that worked for three years in 2017-2020, around $150, will start working as a support level. 4. Short-term channel projection 5. Short-term equal waves from the top: AB=CD The optimal entry point should stay between $147-$160. Good luck!
NYSE:JNJLong
by VaidoVeek
Incoming drops confirmed on Johnson&Johnson. JNJWhere are we going with this one? Very likely further down on the largest pharmaceutical firm in the world. As you can see confirmation has been crossed, signifying a start of a new zigzag. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:JNJShort
by Rykin_Capital
JNJ outperforming BUT M-pattern may retest 163/157 if 170 failsSo far JNJ is outperforming the SPY as staples are a defensive play during uncertain markets. But if JNJ fails to break above my 170 yellow zone (also BO of the black falling wedge) in the next few days then a retest of the 163 green support zone is next. 163 is also a 1.272 Fib zone & also a retest of the blue upchannel base. This is an ideal spot to end the M-pattern to start a new uptrend validating the blue upchannel. Although less probable for the near term, a retest of the 157 red zone may occur if the blue channel breaks as this is the upper side of a big red channel started in 2004. Not trading advice
NYSE:JNJLong
by xtremerider8
$JNJ to make new ATH's$JNJ looks primed and ready to make new all-time highs this week. JNJ is in an ascending channel and based on RSI staying above 50 combined with MACD building and not near its relative "max" (about 4.44), this stock looks like it has legs. I think it is about to break through resistance relatively easily. With this risky, volatile, day-to-day market, healthcare will be one of the sectors to hide out in and have relative stability and more potential for upside. A good defensive place to be that can be a lucrative trade/investment. JNJ is the best-in-breed, blue-chip with a solid diversified portfolio and potential for capital appreciation alongside a 2.40% dividend yield. Healthcare is going to be a killer sector to be in if you have about a 5-year time horizon. During tightening cycles, tech, energy, and utilities do well, but I do see healthcare being one of the need-to-be in sectors going forward.
NYSE:JNJLong
by EBITDAtiger
Johnson and Johnson at Key Resistance? Johnson and Johnson - Short Term - We look to Sell at 176.93 (stop at 178.95) Previous resistance located at 176.00. We look to sell rallies. This provides an excellent risk/reward opportunity to fade the current bullish move. Although the anticipated move lower is corrective, it does offer ample risk/reward today. Our profit targets will be 172.09 and 168.20 Resistance: 176.00 / 180.00 / 200.00 Support: 170.00 / 165.00 / 155.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading . The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:JNJShort
by Saxo
SBFM - Sunshine Biopharma Doing BIG Things!Always DYOR and understand the dynamics of these OTC stocks (known for pump & dump) but the fundamentals here are what will ultimately drive Sunshine Biopharma to return to it's formerly glorious highs but for now, it's relegated to the fractional levels that we see. On it's face, it looks like a no-brainer . . company shedding debt, increasing earnings (still no real profitability) BUT, a recent patent publication and a litany of amazing solutions in the areas of drug-resistant cancers, COVID-19, etc. But don't take my word for it . . check it out . . sunshinebiopharma.com Caveat Emptor - The evil corporate empire will probably try to keep this one squashed and on the DL with massive shorting (if I had to guess) and for several reasons 1. Competition 2. Cancer is big business and people that cure it tend to go away quickly 3. Keep the price low with the help of WS peckerwoods for a cheaper acquisition Again, I don't render professional investment advice, I just read charts and try to tie the fundamentals into a more complete picture. The Fib channel looks attractive in an uptrend, we just got a nice bump up above the 50/200 EMA and we know what kind of price history this beauty has so it's worth an add. I've got a DCA bag and will LTBH it for either a buyout or until the WS woods drive it to zero, whatever the outcome . . no risk, no reward. Good luck!
SLong
by FudBox
8